Denovo Biopharma

The Team of Advisors Consists of Industry Veterans and Academic Leaders

K. Peter Hirth, Ph.D.

K. Peter Hirth, Ph.D., co-founder and formerly Chief Executive Officer of Plexxikon, Inc., has over 30 years of biotechnology and pharmaceutical discovery and development experience and currently serves as a board member of Spinomix, KineMed, Kolltan Pharmaceuticals, and Afferent Pharmaceuticals. From 2001 to 2013 at Plexxikon, Dr. Hirth built a novel, structure-guided drug discovery platform, which brought several new chemical entities into the clinic, including Zelboraf®, an FDA-approved therapy for metastatic melanoma together with a companion diagnostic. From 1991-2000, as Sugen Inc.’s President and Founder, Dr. Hirth was instrumental in building the company from its inception and in advancing several kinase inhibitors through clinical trials in oncology. Prior to Sugen, he was Vice President of Research at Boehringer Mannheim where he successfully led the company’s erythropoietin program to approval in 1989. Dr. Hirth was a research scientist with the Max Planck Institute. He completed his post-doctoral work at the University of California, San Diego and received his Ph.D. in Molecular Genetics from Heidelberg University, Germany.

Steven Leventer, Ph.D.

Dr. Leventer has over 28 years of experience in all phases of drug development. His unique skill set is derived from large pharma, startups, and CRO seasoning. His extensive experience includes direction of well over 100 clinical trials, from single studies to entire development programs across multiple indications and all phases of drug development. His extensive interactive experience with national regulatory agencies, has led multiple regulatory meetings with the FDA and EU boards of health. He is a highly entrepreneurial drug developer with excellent financial and strong management skills. His previous professional experience includes Quintiles, Vela Pharmaceuticals, Wyeth, and Astra Zeneca. Dr. Leventer was trained as a neurochemist, with post-doctoral fellowships and faculty appointments at the University of Texas, Western Psychiatric Institute and Clinic, and Loyola University Stritch School of Medicine.

John M. Davis, M.D.

Dr. Davis is a world-renowned physician scientist in psychiatry clinical research. Dr. Davis is interested in the biologic basis of major mental illness and its treatment with medication. He and his colleagues introduced the paradigm to psychiatry that major mental illness may be caused by biochemical abnormalities. His group was among the first to do studies on the pharmacodynamics and pharmacokinetics of psychotropic drugs. His educational film to teach the recognition of certain side effects to physicians won a Telly award, the equivalent of an Academy Award for education industry films. He was among the first of several physicians to introduce meta-analysis as a tool to pool scientific data. Dr. Davis attended Princeton University, received his medical degree from Yale University School of Medicine, interned at Massachusetts General Hospital, and completed his psychiatric residency at Yale University School of Medicine. He received his research training at the National Institutes of Health. He is now in the department of psychiatry at the University of Illinois, Chicago School of Medicine.